DE60209471D1 - Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii - Google Patents

Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii

Info

Publication number
DE60209471D1
DE60209471D1 DE60209471T DE60209471T DE60209471D1 DE 60209471 D1 DE60209471 D1 DE 60209471D1 DE 60209471 T DE60209471 T DE 60209471T DE 60209471 T DE60209471 T DE 60209471T DE 60209471 D1 DE60209471 D1 DE 60209471D1
Authority
DE
Germany
Prior art keywords
topoisomerase
succinimide
derivatives
maleimid
maleimide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60209471T
Other languages
English (en)
Inventor
Buhl Jensen
Birgitte Sokilde
Vang Carstensen
W Langer
Andrew Creighton
Maxvell Sehested
Hallund Jensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onxeo DK
Original Assignee
Topotarget AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget AS filed Critical Topotarget AS
Application granted granted Critical
Publication of DE60209471D1 publication Critical patent/DE60209471D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60209471T 2001-03-29 2002-03-27 Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii Expired - Fee Related DE60209471D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100522 2001-03-29
PCT/DK2002/000213 WO2002078679A2 (en) 2001-03-29 2002-03-27 Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors

Publications (1)

Publication Number Publication Date
DE60209471D1 true DE60209471D1 (de) 2006-04-27

Family

ID=8160403

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60209471T Expired - Fee Related DE60209471D1 (de) 2001-03-29 2002-03-27 Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii

Country Status (5)

Country Link
EP (1) EP1373494B1 (de)
AT (1) ATE318596T1 (de)
AU (1) AU2002249103A1 (de)
DE (1) DE60209471D1 (de)
WO (1) WO2002078679A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002322323A1 (en) 2001-06-25 2003-01-08 Massachusetts Institute Of Technology Bioerodible conducting materials
CA2476825C (en) 2002-02-21 2011-04-05 Aprea Ab Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
US7723376B2 (en) * 2003-07-15 2010-05-25 Korea Research Institute Of Bioscience And Biotechnology 2-oxo-heterocyclic compounds and pharmaceutical compositions
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
GB9605533D0 (en) * 1996-03-15 1996-05-15 Unilever Plc Modified aluminosilicate
DE19838506C2 (de) * 1998-05-04 2000-08-31 Asta Medica Ag Indolderivate und deren Verwendung zur Behandlung von malignen und anderen, auf pathologischen Zellproliferationen beruhenden Erkrankungen
ES2234300T3 (es) * 1998-10-08 2005-06-16 Smithkline Beecham Plc 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
AU769533B2 (en) * 1999-03-12 2004-01-29 Clinigen Group Plc Treatment of accidental extravasation of anthracyclines
NZ522767A (en) * 2000-05-15 2004-07-30 Celgene Corp Thalidomide and a topoisomerase inhibitor for the treatment of cancer

Also Published As

Publication number Publication date
ATE318596T1 (de) 2006-03-15
WO2002078679A2 (en) 2002-10-10
EP1373494B1 (de) 2006-03-01
WO2002078679A3 (en) 2002-12-19
AU2002249103A1 (en) 2002-10-15
EP1373494A2 (de) 2004-01-02

Similar Documents

Publication Publication Date Title
DE60026155D1 (de) Einige alkylendiamin-substituierte heterocyclen
NO20080150L (no) Inhibitorer av AKT-aktivitet
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
TR200102020T2 (tr) Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler.
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO20061194L (no) Mitotiske kinesininbibitorer
WO2003049702A8 (en) Vanilloid receptor ligands and their use in treatments
ATE556048T1 (de) Prolinderivate und ihre verwendung als heilmittel
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
DE69922216D1 (de) Porphyrin derivate, ihre verwendung in der photodynamischen therapie und diese enthaltende medizinische geräte
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
ATE444066T1 (de) Liganden für den cannabinoidrezeptoren
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
HUP0300169A2 (en) Pyrrolidines which inhibit camp-specific pde, pharmaceutical compositions containing them and their use
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
EA200500377A1 (ru) Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
ATE538124T1 (de) Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
DE60209471D1 (de) Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii
DE60001586D1 (de) Diphenyl-piperidin derivate
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
EA200601687A1 (ru) Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1
ATE424200T1 (de) Solubilisierte topoisomerase-gift-mittel

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee